Exemestane and Letrozole Interaction

Avoid
Mechanism-based 75% confidence

Exemestane and Letrozole have a potentially harmful interaction with 75% confidence. Both Exemestane and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart and pituitary, so monitoring these systems is recommended.

Compound Profiles

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Half-life: ~24 hours Typical dose: 12.5mg EOD or 25mg E3D (estrogen management) pct, anabolic
androgen receptoraromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Letrozole

Aromatase Inhibitor | Potent Estrogen Suppression

Letrozole competitively and reversibly binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), inhibiting its catalytic activity with greater potency than any other commercially available aromatase inhibitor. Aromatase catalyzes the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~2 days (48 hours) Typical dose: 0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) pct, anabolic
aromatase androgenicaromatase inhibitorhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (Exemestane, Letrozole). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the aromatase-inhibitor safety flag (Exemestane, Letrozole). Monitor accordingly.
2x 2 hepatotoxic compounds (Exemestane, Letrozole). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Exemestane, Letrozole). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Exemestane, Letrozole). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the pct-agent safety flag (Exemestane, Letrozole). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (Exemestane, Letrozole). Monitor accordingly.

Frequently Asked Questions

Can I take Exemestane with Letrozole?

Combining Exemestane with Letrozole is not recommended. Both Exemestane and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Exemestane and Letrozole safe together?

This combination carries significant risk. Both Exemestane and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Exemestane and Letrozole?

Both Exemestane and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Exemestane and Letrozole?

Exemestane has a half-life of ~24 hours and Letrozole has a half-life of ~2 days (48 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Exemestane vs Letrozole

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.